We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

130 hedge funds and large institutions have $1.24B invested in Arcus Biosciences in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 45 increasing their positions, 46 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

0.5% more ownership

Funds ownership: 63.12% → 63.62% (+0.5%)

1% less capital invested

Capital invested by funds: $1.25B → $1.24B (-$17.4M)

2% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 46

12% less funds holding

Funds holding: 148 → 130 (-18)

38% less call options, than puts

Call options by funds: $7.63M | Put options by funds: $12.3M

56% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 32

Holders
130
Holders Change
-18
Holders Change %
-12.16%
% of All Funds
2.26%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.1%
New
14
Increased
45
Reduced
46
Closed
32
Calls
$7.63M
Puts
$12.3M
Net Calls
-$4.69M
Net Calls Change
+$5.23M

Top Buyers

1
EC
EcoR1 Capital
California
+$32.5M
2
BI
BVF Inc
California
+$26.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.5M
4
BlackRock
BlackRock
New York
+$18.4M
5
State Street
State Street
Massachusetts
+$14.9M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$41.7M
2
Ameriprise
Ameriprise
Minnesota
-$30.6M
3
HM
HealthCor Management
New York
-$15.1M
4
CS
Candriam SCA
Luxembourg
-$10.2M
5
ACM
Asymmetry Capital Management
California
-$6.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
GGHC
26
Gilder Gagnon Howe & Co
New York
$8.16M -$203K -7,124 -2%
Renaissance Technologies
27
Renaissance Technologies
New York
$7.57M +$537K +18,800 +7%
JP Morgan Chase
28
JP Morgan Chase
New York
$7.52M -$2.98M -104,290 -28%
Morgan Stanley
29
Morgan Stanley
New York
$7.4M +$2.71M +94,862 +54%
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$7.38M +$1.42M +49,586 +23%
PHP
31
Parkman Healthcare Partners
Connecticut
$6.77M -$1.98M -69,245 -22%
Deutsche Bank
32
Deutsche Bank
Germany
$6.38M +$2.75M +96,200 +71%
Invesco
33
Invesco
Georgia
$6M -$2.27M -79,524 -27%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$5.59M +$961K +33,662 +20%
PAM
35
Panagora Asset Management
Massachusetts
$5.2M -$77K -2,696 -1%
Millennium Management
36
Millennium Management
New York
$4.74M +$4.14M +144,969 +522%
Citigroup
37
Citigroup
New York
$4.48M +$1.31M +45,873 +39%
Two Sigma Investments
38
Two Sigma Investments
New York
$3.78M +$2.97M +103,883 +307%
DCM
39
DAFNA Capital Management
California
$3.29M +$1.77M +62,100 +108%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$2.88M +$383K +13,397 +15%
First Trust Advisors
41
First Trust Advisors
Illinois
$2.87M -$1.04M -36,519 -26%
PCC
42
Park Circle Company
Maryland
$2.75M +$2.86M +100,000 New
AA
43
ALPS Advisors
Colorado
$2.57M -$684K -23,945 -20%
Swiss National Bank
44
Swiss National Bank
Switzerland
$2.36M -$303K -10,600 -11%
PA
45
Parallel Advisors
California
$2.34M – – –
PIM
46
Platinum Investment Management
Australia
$2.07M – – –
Adage Capital Partners
47
Adage Capital Partners
Massachusetts
$2.06M -$5M -175,000 -70%
BG
48
Bellevue Group
Switzerland
$2.06M – – –
APP
49
Alpha Paradigm Partners
Illinois
$1.98M +$2.06M +71,951 New
Victory Capital Management
50
Victory Capital Management
Texas
$1.95M -$41.7M -1,459,488 -95%
1
2
3 4 5

RCUS Hedge Fund Activity: Q2 2021 in Review

130 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2021, worth a combined $1.24B — down 1.4% from $1.25B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of RCUS and 14 opened new positions — a net loss of 18 holders — while 46 trimmed existing stakes and 45 added.

The largest buyer was EcoR1 Capital, adding an estimated $32.5M. The largest seller was Victory Capital Management, cutting an estimated $41.7M.

  • 130 institutional investors held Arcus Biosciences (RCUS) as of Q2 2021, down from 148 in Q1 2021.
  • Funds reported $1.24B of Arcus Biosciences stock for Q2 2021, down 1.4% quarter-over-quarter.
  • 14 funds opened new Arcus Biosciences positions in Q2 2021 and 32 closed out, a net change of -18 holders.
  • The largest Arcus Biosciences buyer in Q2 2021 was EcoR1 Capital, an estimated $32.5M added.
  • The largest Arcus Biosciences seller in Q2 2021 was Victory Capital Management, an estimated $41.7M sold.

Based on aggregated 13F filings for Q2 2021.